Damloran Pharmaceutical (XTEH:DAML1) Debt-to-EBITDA : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTEH:DAML1 Damloran Pharmaceutical XTEH:DAML1
27 GF Score
Price IRR10,100.00
View Full Analysis

What is Damloran Pharmaceutical Debt-to-EBITDA?

Damloran Pharmaceutical XTEH:DAML1 27 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates XTEH:DAML1 with a GF Score™ of 27/100.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Damloran Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Damloran Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Damloran Pharmaceutical's annualized EBITDA for the quarter that ended in . 20 was IRR0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Damloran Pharmaceutical's Debt-to-EBITDA or its related term are showing as below:

XTEH:DAML1's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.64
* Ranked among companies with meaningful Debt-to-EBITDA only.

Damloran Pharmaceutical  (XTEH:DAML1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Damloran Pharmaceutical Debt-to-EBITDA Related Terms

Damloran Pharmaceutical Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Damloran Pharmaceutical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Damloran Pharmaceutical Debt-to-EBITDA Chart

Damloran Pharmaceutical Annual Data
Trend
Debt-to-EBITDA

Damloran Pharmaceutical Semi-Annual Data
Debt-to-EBITDA

XTEH:DAML1 vs IMNPQ: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Damloran Pharmaceutical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Damloran Pharmaceutical Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Damloran Pharmaceutical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Damloran Pharmaceutical's Debt-to-EBITDA falls into.


XTEH:DAML1
27GF Score
Damloran Pharmaceutical XTEH:DAML1
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Damloran Pharmaceutical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Damloran Pharmaceutical's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / N/A
=N/A

Damloran Pharmaceutical's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Damloran Pharmaceutical (XTEH:DAML1) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Damloran Pharmaceutical.
Is Damloran Pharmaceutical's Debt-to-EBITDA too high?
Damloran Pharmaceutical's current Debt-to-EBITDA is 0.00. Overall, Damloran Pharmaceutical has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Damloran Pharmaceutical's Debt-to-EBITDA compare to IMNPQ?
Damloran Pharmaceutical's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 677 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Damloran Pharmaceutical. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Damloran Pharmaceutical's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Damloran Pharmaceutical stock overvalued right now?
Damloran Pharmaceutical (XTEH:DAML1) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Damloran Pharmaceutical's overall GF Score™ is 27/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Damloran Pharmaceutical (XTEH:DAML1), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Damloran Pharmaceutical Business Description

Address No.4, Parvin Alley, West Fatemi Avenue, Tehran, IRN
Damloran Pharmaceutical manufactures and markets livestock and poultry pharmaceuticals. The Company offers animal health products to protect and improve health and hygiene of society to treat and to enhance the quality of animals' life.
27GF Score

Get the complete analysis for XTEH:DAML1

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

IRR10,100.00
Price